We are live on ! Find out more
CLRB icon

Cellectar Biosciences
CLRB

11 hedge funds and large institutions have $593K invested in Cellectar Biosciences in 2019 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 11 → 11 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0.33% less ownership

Funds ownership: 7.77% → 7.44% (-0.33%)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

81% less capital inflows, than outflows

Capital inflows: $6.7K | Capital outflows: $35.8K

Holders
11
Holders Change
–
Holders Change %
0%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$6.09K
2
AllSquare Wealth Management
AllSquare Wealth Management
New York
+$609

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$26.2K
2
UBS Group
UBS Group
Switzerland
-$9K
3
Renaissance Technologies
Renaissance Technologies
New York
-$609

CLRB Hedge Fund Activity: Q1 2019 in Review

11 of the 4,634 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q1 2019, worth a combined $593K — up 44% from $413K a quarter earlier.

Fund positioning in CLRB was balanced in Q1 2019: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 2 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $6.09K. The largest seller was Morgan Stanley, cutting an estimated $26.2K.

  • 11 institutional investors held Cellectar Biosciences (CLRB) as of Q1 2019, unchanged from Q4 2018.
  • Funds reported $593K of Cellectar Biosciences stock for Q1 2019, up 44% quarter-over-quarter.
  • 1 fund opened new Cellectar Biosciences positions in Q1 2019 and 1 closed out, a net change of 0 holders.
  • The largest Cellectar Biosciences buyer in Q1 2019 was Citadel Advisors, an estimated $6.09K added.
  • The largest Cellectar Biosciences seller in Q1 2019 was Morgan Stanley, an estimated $26.2K sold.

Based on aggregated 13F filings for Q1 2019.